Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 09 05 2020
revised: 01 06 2020
accepted: 02 06 2020
entrez: 5 7 2020
pubmed: 6 7 2020
medline: 14 7 2020
Statut: ppublish

Résumé

The synchronous diagnosis of two or more primary malignancies in a patient is overall rare. This is a case report of a 70-year-old female with a history of skin squamous cell carcinoma presenting with occult hematochezia. Colonoscopy and biopsy results confirmed a microsatellite stable (MMS) adenocarcinoma in the ascending colon, and subsequent computed tomography (CT) scans identified a 3.2 cm right colonic mass and a 5.0 cm mass in the pancreatic body. Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) confirmed the presence of pancreatic ductal adenocarcinoma (PDAC). The patient underwent neo-adjuvant FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin) chemotherapy prior to the simultaneous distal pancreatectomy and right hemicolectomy for both pancreatic and colonic tumors. The pathology diagnoses included moderately differentiated pancreatic ductal carcinoma (PDAC) with histiocyte-like features (tumor stage: ypT3N1M0) and moderately differentiated colonic adenocarcinoma, intestinal type (tumor stage: ypT3N0M0). To the best of our knowledge, this is the first documented case of synchronous primary colonic adenocarcinoma and PDAC in the English literature.

Identifiants

pubmed: 32620648
pii: 40/7/4029
doi: 10.21873/anticanres.14398
doi:

Substances chimiques

Antineoplastic Agents 0
folfirinox 0
Oxaliplatin 04ZR38536J
Irinotecan 7673326042
Leucovorin Q573I9DVLP
Fluorouracil U3P01618RT

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4029-4032

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Can Cao (C)

Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.
The Warren Alpert Medical School, Brown University, Providence, RI, U.S.A.

Purvi Parikh (P)

Division of Surgical Oncology, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.

Koorosh Moezardalan (K)

Division of Gastroenterology, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.

Archana Anantharaman (A)

Division of Medical Oncology, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.

Ali Azarm (A)

Division of Gastroenterology, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.

Jinping Lai (J)

Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A. Jinping.X.Lai@kp.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH